{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T06:43:30Z","timestamp":1782456210041,"version":"3.54.5"},"reference-count":59,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Renal failure is one of the most important manifestations of multiple myeloma. It is caused by renal lesions such as cast nephropathy, immunoglobulin deposition disease, AL amyloidosis or other glomerular and\/or tubular diseases, mostly due to the toxic effect of free light chains in serum. Renal failure can represent a clinical emergency and is associated with poor outcome in newly diagnosed and relapsed\/refractory multiple myeloma patients. Although progression-free survival and overall survival have improved with the introduction of novel agents, renal failure remains a challenge for the treatment of patients with multiple myeloma. Monoclonal antibodies are a component of therapy for newly diagnosed and relapsed\/refractory patients and, based on clinical trials and real-world experience, are also safe and effective for subjects with renal failure, even if they are on dialysis. Most of the data are on anti-CD38 and anti-SLAM7 antibodies, but new antibody\u2013drug conjugates such as belantamab mafodotin and bispecific antibodies also appear to be effective in myeloma kidney disease. In the future, we will have to face some challenges, such as defining new criteria for renal response to treatment, defining specific trials for these difficult-to-treat patients and integrating different therapeutic options.<\/jats:p>","DOI":"10.3390\/ph17081029","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T13:57:28Z","timestamp":1722866248000},"page":"1029","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Role of Monoclonal Antibodies in the Treatment of Myeloma Kidney Disease"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0997-4157","authenticated-orcid":false,"given":"Daniele","family":"Derudas","sequence":"first","affiliation":[{"name":"S.C. di Ematologia e C.T.M.O. Ospedale Oncologico di Riferimento Regionale \u201cA. Businco\u201d ARNAS \u201cG. Brotzu\u201d, 09126 Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Chiriu","sequence":"additional","affiliation":[{"name":"S.C. di Ematologia e C.T.M.O. Ospedale Oncologico di Riferimento Regionale \u201cA. Businco\u201d ARNAS \u201cG. Brotzu\u201d, 09126 Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International Myeloma Working Group Recommendations","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/10428190601126602","article-title":"Renal failure in Multiple Myeloma","volume":"48","author":"Bamias","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/17474086.2016.1210003","article-title":"Managing Renal Complications In Multiple Myeloma","volume":"9","author":"Fotiou","year":"2016","journal-title":"Expert Rev. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jgo.2017.09.007","article-title":"The impact of age and comorbidities on practice patterns","volume":"9","author":"Hari","year":"2018","journal-title":"J. Geriatr. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e23416","DOI":"10.1002\/jcla.23416","article-title":"Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients","volume":"34","author":"Chen","year":"2020","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1038\/bcj.2015.20","article-title":"Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma","volume":"5","author":"Gonsalves","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002\u2014Medical Research Council Adult Leukaemia Working Party","volume":"23","author":"Augustson","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.kint.2020.11.010","article-title":"Management of acute kidney injury in symptomatic multiple myeloma","volume":"99","author":"Bridoux","year":"2021","journal-title":"Kidney Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","article-title":"The evaluation of monoclonal gammopathy of renal significance: A consensus report of the International Kidney and Monoclonal Gammopathy Research Group","volume":"15","author":"Leung","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/ajh.26566","article-title":"Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors","volume":"97","author":"Gozzetti","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical Efficacy of Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): Overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_23","first-page":"e528","article-title":"Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"Hemasphere"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"E226","DOI":"10.1002\/ajh.27001","article-title":"Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed\/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study","volume":"98","author":"Kastritis","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S2352-3026(20)30081-8","article-title":"Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: Final results from the phase 2 GEN501 and SIRIUS trials","volume":"7","author":"Usmani","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5045\/br.2020.55.1.65","article-title":"Daratumumab in dialysis-dependent multiple myeloma","volume":"55","author":"Jeyaraman","year":"2020","journal-title":"Blood Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s12185-020-02948-0","article-title":"Successful management of hemodialysis-dependent refractory myeloma with modified daratumumab, bortezomib and dexamethasone regimen","volume":"112","author":"Mizuno","year":"2020","journal-title":"Int. J. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.3324\/haematol.2018.191122","article-title":"Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma","volume":"103","author":"Rocchi","year":"2018","journal-title":"Haematologica"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"E289","DOI":"10.1111\/bjh.16286","article-title":"Single-agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: Results of a Spanish retrospective, multicentre study","volume":"190","author":"Cejalvo","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"E33","DOI":"10.1111\/bjh.17412","article-title":"Safety and efficacy of daratumumab in patients with multiple myeloma and severe renal failure","volume":"193","author":"Kuzume","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2023.41.16_suppl.8057","article-title":"A phase 2 evaluation of daratumumab-based induction therapy in patients with multiple myeloma with severe renal insufficiency","volume":"41","author":"Harvey","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6691","DOI":"10.1182\/blood-2023-185362","article-title":"Efficacy and Safety of Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma with Renal Insufficiency in Real-World: A Non-Interventional Prospective Multicenter Observational Study","volume":"142","author":"Fu","year":"2023","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e20024","DOI":"10.1200\/JCO.2018.36.15_suppl.e20024","article-title":"Impact of baseline renal function on efficacy and safety of daratumumab plus bortezomib-melphalan-prednisone (VMP) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE)","volume":"36","author":"Cavo","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2021-146940","article-title":"Efficacy of daratumumab, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma and impaired renal function from the phase 3 MAIA study based on lenalidomide starting dose","volume":"138","author":"Usmani","year":"2021","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): Results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","article-title":"Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: Extended follow-up of POLLUX, a randomized, open-label, phase 3 study","volume":"34","author":"Bahlis","year":"2020","journal-title":"Leukemia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): An open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-14-0695","article-title":"SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies","volume":"20","author":"Deckert","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): A randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41375-020-0868-z","article-title":"Isatuximab plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis","volume":"35","author":"Dimopoulos","year":"2021","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): A multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2020-136415","article-title":"Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis","volume":"136","author":"Capra","year":"2020","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000519783","article-title":"Isatuximab plus pomalidomide and dexamethasone in a patient with dialysis-dependent multiple myeloma","volume":"66","author":"Takakuwa","year":"2021","journal-title":"Chemotherapy"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/jha2.743","article-title":"Difficult-to-treat patients with relapsed\/refractory multiple myeloma: A review of clinical trial results","volume":"4","author":"Raab","year":"2023","journal-title":"EJHaem"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti- B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"8519","DOI":"10.1200\/JCO.2020.38.15_suppl.8519","article-title":"DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed\/refractory multiple myeloma (RRMM) and renal impairment","volume":"38","author":"Lee","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_50","unstructured":"TECVAYLI (Teclistamab-Cqyv) Injection (2024, February 01). Prescribing Information. Available online: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribinginformation\/TECVAYLI-pi.pdf."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of monoclonal antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"E322","DOI":"10.1002\/ajh.27063","article-title":"Teclistamab in patients with multiple myeloma and impaired renal function","volume":"98","author":"Joiner","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1182\/blood-2023-180660","article-title":"Teclistamab in Relapsed Refractory Multiple Myeloma Patients on Dialysis: A French Experience","volume":"142","author":"Lachenal","year":"2023","journal-title":"Blood"},{"key":"ref_55","unstructured":"European Medicines Agency (2023). Talvey\u00ae Sumary of Product Characteristics, European Medicines Agency."},{"key":"ref_56","unstructured":"European Medicines Agency (2023). Elrexfio\u00ae Sumary of Product Characteristics, European Medicines Agency."},{"key":"ref_57","first-page":"46","article-title":"Elranatamab treatment in a multiple myeloma patient undergoing renal dialysis","volume":"6","author":"Chedeville","year":"2024","journal-title":"Clin. Hematol. Int."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S1470-2045(23)00223-1","article-title":"Management of multiple myeloma-related renal impairment: Recommendations from the International Myeloma Working Group","volume":"24","author":"Dimopoulos","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1080\/10428194.2020.1867725","article-title":"Renal insufficiency in multiple myeloma: A systematic review and meta-analysis of all randomized trials from 2005\u20132019","volume":"62","author":"Mohyuddin","year":"2021","journal-title":"Leuk. Lymphoma"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/8\/1029\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:30:22Z","timestamp":1760110222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/8\/1029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":59,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["ph17081029"],"URL":"https:\/\/doi.org\/10.3390\/ph17081029","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,5]]}}}